Vision Shopsters: Neuropathic Pain: Competing Treatments and Market Entry Considerations

Vision Shopsters: Neuropathic Pain: Competing Treatments and Market Entry Considerations

This report presents the findings of a global study of current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 330 clinics, who provided details of their treatments and prescribing practices. This was carried out as part of a competitor insight and market entry study, in the neuropathic pain field.

With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.

Overview :

Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries

In-depth information relevant to markets and opportunities in the NP field

98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment

Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium

74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin

Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients

Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available

A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)

An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions

Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP

For more information on the report, kindly visit :

http://www.visionshopsters.com/product/3357/Neuropathic-Pain-Competing-Treatments-and-Market-Entry-Considerations.html

or email us your query at :info@visionshopsters.com

----------------------------------------------

POST COMMENT

Essay Writing Services: How to Spot Scams and Poor Quality Bajaj plans planning a 100cc bike for Indian markets Vision Shopsters: Stroke: Competing Treatments and Market Entry Considerations Here comes the Apple iPhone 4 on 24th June in UK Market Get Reliable Stock Market Investing Advice From Thedowtheory.Com Online Marketing Tips: Where to Get Accurate Tips Online Today How To Avoid Disappointed With Online Marketing - A Review of Empire Formula Commodity Market place Rounds - Essential to Worthwhile Investing Niche Marketing Success - Essential Reminders Niche Marketing Products - The Fundamentals How to Be an Online Marketer Profitable And Legit Ways To Make Money Online Online Marketing Checklist